The regulation of biosimilars
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Transplantation today: what are the key messages
Why do charities need to keep funding research into leukemia and blood cancer in general?
Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years